Med-IQ
Opioid Addiction, Psychiatric Comorbidities, and Their Effects on HCV Infection
E-publication E-publication

Opioid Addiction, Psychiatric Comorbidities, and Their Effects on HCV Infection


Presented by the Johns Hopkins University School of Medicine. Developed in collaboration with Med-IQ.
Johns Hopkins University School of MedicineMed-IQ

Time to Complete:
45 minutes
Released:
12/9/16
Expires:
12/8/17

Maximum Credits:

0.75 AMA PRA Category 1 Credit(s)
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

E-publication E-publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.
Time to Complete:
45 minutes

Released:
12/9/16

Expires:
12/8/17

Maximum Credits:
0.75 AMA PRA Category 1 Credit(s)
Share on:
E-publication E-publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Share on:


Time to Complete:
45 minutes
Released:
12/9/16
Expires:
12/8/17


Maximum Credits:
0.75 AMA PRA Category 1 Credit(s)


Overview: This online CME publication explains the rationale for HCV screening among people who inject drugs and offers strategies for mitigating risk and treating HCV, particularly among those with addiction and psychiatric issues.

Faculty

Mark Sulkowski, MD

Professor of Medicine

Medical Director, Viral Hepatitis Center

Division of Infectious Diseases and Gastroenterology and Hepatology

Johns Hopkins University School of Medicine

Baltimore, MD

Glenn J. Treisman, MD, PhD

Eugene Meyer III Professor of Psychiatry and Medicine

Director of AIDS Psychiatry Service

Co-Director of the Chronic Pain Treatment Program

Johns Hopkins University School of Medicine

Baltimore, MD


Disclosure Policy

It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).  Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity.  Detailed disclosure will be made in the course handout materials.


Disclosure Statement

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Mark Sulkowski, MD
Consulting fees/advisory boards: AbbVie Inc., Cocrystal Pharma, Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co. Inc., Trek Therapeutics
 
Glenn J. Treisman, MD, PhD, has indicated no real or apparent conflicts. 

Planning Committee 
Amy Burdette, PhD
Raven Minervino
Lisa R. Rinehart, MS, ELS
  
No planner has indicated that they have any financial interests or relationships with a commercial entity.
 
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s). 


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by educational grants from AbbVie and Gilead Sciences, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.